Elanco Animal Health Incorporated (NYSE:ELAN) Receives $16.75 Consensus Price Target from Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned an average recommendation of “Hold” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $16.75.

A number of research analysts have weighed in on the company. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Barclays boosted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. UBS Group assumed coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 target price on the stock. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $11.73 on Monday. The firm’s 50 day moving average is $13.07 and its 200 day moving average is $14.21. The stock has a market capitalization of $5.80 billion, a P/E ratio of 29.33, a PEG ratio of 2.03 and a beta of 1.41. Elanco Animal Health has a 12 month low of $11.40 and a 12 month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business’s revenue for the quarter was down 3.6% on a year-over-year basis. During the same period last year, the company earned $0.18 earnings per share. On average, sell-side analysts anticipate that Elanco Animal Health will post 0.92 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of ELAN. Benjamin F. Edwards & Company Inc. boosted its stake in Elanco Animal Health by 337.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after buying an additional 1,361 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in shares of Elanco Animal Health in the 3rd quarter worth approximately $29,000. nVerses Capital LLC purchased a new stake in shares of Elanco Animal Health in the 2nd quarter valued at $32,000. AM Squared Ltd bought a new position in shares of Elanco Animal Health during the 3rd quarter valued at $34,000. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Elanco Animal Health during the 3rd quarter valued at $35,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.